黄花蒿花粉变应原舌下滴剂治疗季节性变应性鼻炎的疗效观察与依从性分析
单中心对照研究纳入2021年7—9月山西医科大学第一医院耳鼻喉科门诊80例黄花蒿花粉过敏的季节性变应性鼻炎患者,40例接受舌下免疫治疗(SLIT组)、40例仅对症药物治疗(对照组)。治疗前两组各项评分差异无统计学意义,治疗后第一年花粉高峰期SLIT组各项评分低于对照组且较治疗前降低;SLIT组未出现明显不良反应,脱落12例,依从率70%。作者认为黄花蒿花粉舌下滴剂治疗1年可能改善症状,但依从性较差,有待通过患者教育提高。
要点
- 治疗后第一年花粉高峰期SLIT组TRSS、VAS、TMS、CSMRS均低于对照组,差异有统计学意义(P<0.05)。
- SLIT组治疗后第一年花粉高峰期各项评分较治疗前降低,差异有统计学意义(P<0.05)。
- SLIT组用药期间未出现明显不良反应,脱落12例,依从率70%。
核心结论
- 使用黄花蒿花粉舌下滴剂治疗1年可能改善蒿属花粉期黄花蒿花粉引起的季节性变应性鼻炎患者的症状。
- 由于患者对免疫治疗缺乏足够的认识或者难以坚持规范化用药,接受舌下免疫治疗的依从性较差,故有待通过患者教育进一步提高舌下免疫治疗的依从性。
研究设计与样本
- 本研究采用单中心对照研究,于2021年7—9月共纳入80例就诊于山西医科大学第一医院耳鼻喉科门诊对黄花蒿花粉过敏的季节性变应性鼻炎患者。
- 其中40例接受舌下免疫治疗作为舌下免疫治疗组(SLIT组),另40例仅接受对症药物治疗作为对照组。
- 记录并比较两组治疗开始前蒿属花粉高峰期与治疗后第一年蒿属花粉高峰期的TRSS、VAS、TMS、CSMRS,并跟踪分析脱落情况、安全性及影响依从性因素。
主要发现
- 治疗前蒿属花粉高峰期两组TRSS(SLIT组12.393±3.023 vs 对照组12.450±3.029,t=-0.077,P=0.939)、VAS(SLIT组8.357±1.026 vs 对照组8.400±0.982,t=-0.173,P=0.862)、TMS(SLIT组3.214±0.568 vs 对照组3.175±0.501,t=0.301,P=0.764)、CSMRS(SLIT组5.286±0.680 vs 对照组5.253±0.677,t=0.199,P=0.843)组间比较差异均无统计学意义(P>0.05)。
- 治疗后第一年花粉高峰期SLIT组各项评分低于对照组:TRSS(SLIT组3.964±1.551 vs 对照组7.750±2.169,t=-7.918,P<0.05)、VAS(SLIT组2.893±0.956 vs 对照组5.175±1.481,t=-8.286,P<0.05)、TMS(SLIT组1.821±0.863 vs 对照组3.175±0.501,t=-8.163,P<0.05)、CSMRS(SLIT组2.489±0.921 vs 对照组4.468±0.601,t=-10.723,P<0.05),组间比较差异均有统计学意义(P<0.05)。
- SLIT组治疗后第一年花粉高峰期各项评分较治疗前降低:TRSS(治疗前12.393±3.023 vs 治疗后3.964±1.551,t=20.576,P<0.05)、VAS(治疗前8.357±1.026 vs 治疗后2.893±0.956,t=30.070,P<0.05)、TMS(治疗前3.214±0.568 vs 治疗后1.821±0.863,t=7.151,P<0.05)、CSMRS(治疗前5.286±0.680 vs 治疗后2.489±0.921,t=14.533,P<0.05),治疗前后比较差异均有统计学意义(P<0.05)。
- SLIT组患者用药期间未出现明显不良反应;SLIT组共有12例患者脱落,依从率为70%。
- 脱落原因分别为用药疗程长(4例,33%)、药物价格昂贵(3例,25%)、工作生活因素(3例,25%)、疫情影响(2例,17%)。
关键数值与推荐
- 治疗后第一年花粉高峰期SLIT组TRSS为3.964±1.551,对照组为7.750±2.169(t=-7.918,P<0.05)。
- 治疗后第一年花粉高峰期SLIT组VAS为2.893±0.956,对照组为5.175±1.481(t=-8.286,P<0.05)。
- 治疗后第一年花粉高峰期SLIT组TMS为1.821±0.863,对照组为3.175±0.501(t=-8.163,P<0.05)。
- 治疗后第一年花粉高峰期SLIT组CSMRS为2.489±0.921,对照组为4.468±0.601(t=-10.723,P<0.05)。
- SLIT组依从率为70%,脱落12例。
临床怎么用
- 作者认为,使用黄花蒿花粉舌下滴剂治疗1年可能改善蒿属花粉期黄花蒿花粉引起的季节性变应性鼻炎患者的症状。
- 作者建议,有待通过患者教育进一步提高舌下免疫治疗的依从性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To study the efficacy and compliance analysis of pollen allergen drops in the treatment of allergic rhinitis. The method of single-center controlled was used to analyze the dates' results. From July 2021 to September 2021, 80 patients with seasonal allergic rhinitis were referred to the clinic of otorhinolaryngology in First Hospital of Shanxi Medical University.40 patients received sublingual immunotherapy (SLIT group), and the other 40 patients received symptomatic drug treatment as the control group. The total rhinoconjunctivitis symptom score (TRSS), the visual analogue scale(VAS), total medication score (TMS) and combined scores of medication and rhinoconjunctivitis symptoms (CSMRS) of the patient before the start of the treatment and after the first year of the treatment were compared to assess the efficacy of sublingual immunotherapy of Artemisia pollen. Follow the shedding during the study, the safety of the drug and the causes for compliance analysis were analyzed and recorded. The results of comparison with TRSS, VAS, TMS and CSMRS in two groups in the period of pretherapy were as follows: TRSS(12.393±3.023, 12.450±3.029, t=-0.077, P=0.939), VAS(8.357±1.026, 8.400±0.982, t=-0.173, P=0.862), TMS(3.214±0.568, 3.175±0.501, t=0.301, P=0.764), CSMRS (5.286±0.680, 5.253±0.677, t=0.199, P=0.843), there was no significant difference (P>0.05); lower observed symptom scores were got in the post-treatment pollen peak SLIT group compared to the control group, TRSS(3.964±1.551, 7.750±2.169, t=-7.918, P<0.05), VAS(2.893±0.956, 5.175±1.481, t=-8.286, P<0.05), TMS (1.821±0.863, 3.175±0.501, t=-8.163, P<0.05), CSMRS (2.489±0.921, 4.468±0.601, t=-10.723, P<0.05), and the differences between the groups were statistically significant (P<0.05); the SLIT group significantly reduced all symptom scores at the first peak compared to the starting, TRSS(12.393±3.023, 3.964±1.551, t=20.576, P<0.05), VAS (8.357±1.026, 2.893±0.956, t=30.070, P<0.05), TMS (3.214±0.568, 1.821±0.863, t=7.151, P<0.05), CSMRS(5.286±0.680, 2.489±0.921, t=14.533, P<0.05) and there was statistical difference (P<0.05). No significant adverse reactions occured during medication in the SLIT group. A total of 12 cases were shed in the SLIT group, so the compliance rate was 70%. The four reasons were that patients considered the course was long (4 cases, 33%); the drugs were expensive (3 cases, 25%); patients were busy with their work and life (3 cases, 25%); patients were affected by the outbreak (2 cases, 17%). In summary, Artemisia pollen sublingual drops may improve the symptoms of the patients who got allergic rhinitis caused by Artemisia pollen after the treatment for one year. However, due to the lack of sufficient understanding of immunotherapy or the difficulty in adhering to standardized medication, the compliance with sublingual immunotherapy is still poor, the compliance with sublingual immunotherapy needs to be further improved through patient education. 探讨黄花蒿花粉变应原舌下滴剂对季节性变应性鼻炎进行免疫治疗的疗效及其影响免疫治疗的依从性因素。本研究采用单中心对照研究,于2021年7—9月,共纳入80例就诊于山西医科大学第一医院耳鼻喉科门诊对黄花蒿花粉过敏的季节性变应性鼻炎患者,其中40例接受舌下免疫治疗作为舌下免疫治疗组(SLIT组),另40例仅接受对症药物治疗作为对照组。记录并比较两组患者在治疗开始前蒿属花粉高峰期、治疗后第一年蒿属花粉高峰期的鼻结膜炎症状总评分(total rhinoconjunctivitis symptom score,TRSS)、视觉模拟量表评分(the visual analogue scale,VAS)、总用药评分(total medication score,TMS)、药物鼻结膜炎症状联合评分(combined scores of medication and rhinoconjunctivitis symptoms,CSMRS),用于评估黄花蒿花粉舌下免疫治疗的疗效。跟踪分析研究免疫治疗过程中患者的脱落情况,详细记录脱落原因,分析探讨其安全性及影响免疫治疗依从性因素。结果显示,治疗前蒿属花粉高峰期两组患者TRSS、VAS、TMS、CSMRS比较,TRSS(SLIT组:12.393±3.023,对照组:12.450±3.029,t=-0.077,P=0.939)、VAS(SLIT组:8.357±1.026,对照组:8.400±0.982,t=-0.173,P=0.862)、TMS(SLIT组:3.214±0.568,对照组:3.175±0.501,t=0.301,P=0.764)、CSMRS(SLIT组:5.286±0.680,对照组:5.253±0.677,t=0.199,P=0.843),组间比较差异均无统计学意义(P>0.05);治疗后第一年花粉高峰期SLIT组的相应各项观察评分低于对照组,TRSS(SLIT组:3.964±1.551,对照组:7.750±2.169,t=-7.918,P<0.05)、VAS(SLIT组:2.893±0.956,对照组:5.175±1.481,t=-8.286,P<0.05)、TMS(SLIT组:1.821±0.863,对照组:3.175±0.501,t=-8.163,P<0.05)、CSMRS(SLIT组:2.489±0.921,对照组:4.468±0.601,t=-10.723,P<0.05),组间比较差异均有统计学意义(P<0.05);SLIT组在治疗后第一年花粉高峰期的相应各项评分较治疗前显著降低,TRSS(治疗前:12.393±3.023,治疗后:3.964±1.551,t=20.576,P<0.05)、VAS(治疗前:8.357±1.026,治疗后:2.893±0.956,t=30.070,P<0.05)、TMS(治疗前:3.214±0.568,治疗后:1.821±0.863,t=7.151,P<0.05)、CSMRS(治疗前:5.286±0.680,治疗后:2.489±0.921,t=14.533,P<0.05),治疗前后比较差异均有统计学意义(P<0.05);SLIT组患者用药期间未出现明显不良反应,SLIT组共有12例患者脱落,依从率为70%,脱落原因分别为用药疗程长(4例,33%)、药物价格昂贵(3例,25%)、工作生活因素(3例,25%)、疫情影响(2例,17%)。综上,使用黄花蒿花粉舌下滴剂治疗1年可能改善蒿属花粉期黄花蒿花粉引起的季节性变应性鼻炎患者的症状,但由于患者对免疫治疗缺乏足够的认识或者难以坚持规范化用药,接受舌下免疫治疗的依从性较差,故有待通过患者教育进一步提高舌下免疫治疗的依从性。.
引用
- Yu DD, Liu Y, Zheng ZY, et al. [Efficacy observation and compliance analysis of pollen allergen drops in seasonal allergic rhinitis]. Zhonghua Yu Fang Yi Xue Za Zhi. 2023. PMID: 38186147. doi:10.3760/cma.j.cn112150-20230711-00002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。